News
MP 0420 filed with FDA for EUA in COVID-19
Molecular Partners was informed by Novartis that the company has requested Emergency Use Authorization (EUA) from the FDA for MP 0420 (ensovibep), a DARPin antiviral therapeutic candidate to treat COVID-19.
This submission is based on the totality of the data from clinical and preclinical studies including the positive results of the Phase II portion of the EMPATHY study, a randomized, placebo-controlled study which enrolled 407 symptomatic patients infected with SARS-Cov-2.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins